Mr. Vance Fiegel earned his Bachelor of Science degree in biology at the University of Minnesota, and performed research at the University of Minnesota for 17 years. His research focused on inflammation, infectious diseases, microbiology, and wound healing. Upon leaving the University twenty-three years ago, he co-founded Embro Corporation, a privately held biomedical research and development company. Embro’s proprietary technology portfolio includes technology in medical devices, stem cells and the use of Sphagnum moss for water treatment. He has published over 60 research articles and holds over 25 patents. He also has served as President and Director of Surgidyne, Inc., which before its acquisition was a publicly traded medical device manufacturer.

Mr. Vance Fiegel and Dr. David Knighton have founded a number of companies utilizing their patents and related developments, including the following:

• Curative Technologies, Inc. CTI was founded in 1984. Using patented technologies, CTI established 200 wound care centers around the country, at which patients with non-healing wounds from diabetes, venous stasis, pressure sores and other etiologies were treated with growth factors released from their own platelets. Dr. David Knighton served as Chairman of the Board through 1989 and served with the company through its initial public offering in 1991. Both Dr. David Knighton and Mr. Vance Fiegel served as consultants to CTI through 1995.
• Embro Corporation, founded in 1991, is a research and development company where Dr. David Knighton and Mr. Vance Fiegel develop their innovative ideas and inventions. Embro has capabilities in cell biology, microbiology, biochemistry, and animal models. Currently it is involved in evaluating Sphagnum moss based applications related to biofilm, scale, and corrosion inhibition. Other work continues in the areas of vein harvesting and wound healing/stem cell approaches to cardiovascular and orthopedic diseases. Dr. Knighton is currently Chairman of the Board and Chief Executive Officer. Mr. Fiegel is President and Chief Operating Officer.
• Embro Vascular, LLC, of which Dr. David Knighton is currently Chairman and Mr. Vance Fiegel, is Vice President and Treasurer was established in 1998 to commercialize Embro Corporation’s patented endoscope and method for vein removal. The patented product was licensed to a company that was later purchased by Guidant and is presently owned and marketed by Maquet Cardiovascular, LLC.
• Creative Water Solutions, LLC (CWS), founded in 2003 to develop proprietary technologies derived from Sphagnum moss for water treatment. Dr. David Knighton is Chairman of the Board of Governors and Mr. Vance Fiegel is Chief Scientific Officer and Chief Regulatory Officer.